About Event

Welcome to the Inaugural Cell & Gene Therapy Pricing & Reimbursement Summit

Cell and gene therapies are transforming the healthcare landscape, offering promising solutions for curing diseases and achieving prolonged remission. This event brings together influential stakeholders to tackle issues of access and affordability. Through active engagement and partnership, industry leaders strive to refine pricing methodologies and reimbursement frameworks to improve patient accessibility and ensure the successful introduction of therapies. 




how leading companies are navigating the evolving regulatory landscape to tackle complex challenges and gain strategic insights 

with industry experts to enhance patient access and ensure the success of commercial cell and gene therapy launches

knowledge into the impact of the IRA and the latest pricing models

What our speakers have to say:

“Aligning on key market trends, identifying challenges to access, particularly from a reimbursement standpoint, and developing potential solutions to these challenges are all critical to ensuring individuals may benefit from the transformational innovation of novel cell and gene therapies.”

Laura Okpala, Executive Director, US Reimbursement Policy, Gilead Sciences